Title:Targeting STAT1 in Both Cancer and Insulin Resistance Diseases
VOLUME: 18 ISSUE: 2
Author(s):Chen Meng, Li-bin Guo, Xiaolong Liu, Yih-Hsin Chang and Yao Lin
Affiliation:The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, Fujian Province, P.R. China, 350025., Department of Biotechnology and Laboratory Science in Medicine, National Yang-Ming University, Taipei 112, Taiwan, ROC., College of Life Sciences, Qishan Campus, Fujian Normal University, Fuzhou, Fujian Province, P.R. China, 350117.
Keywords:STAT1, Cancer, insulin resistance diseases, signalling pathway.
Abstract:With the rapid development of targeted therapy and our understanding of the underlying molecular
mechanisms, drug repurposing is becoming trendy in drug development field. Drugs that display
promising therapeutic effects towards multiple diseases tend to target important signaling proteins. Insulin
resistance and obesity are strongly associated and both are reported to be correlated with cancer, suggesting
they may be linked via some critical pathways. Signal transducer and activator of transcription 1
(STAT1) is an important transcription factor involved in the regulation of multiple cellular processes
such as proliferation, survival, inflammation, and angiogenesis. The expression and activity of STAT1 is
misregulated in both insulin resistance diseases and cancer. In this review, we summarize recent progress
on the function and regulation of STAT1 in both cancer and insulin resistance diseases. Drugs and small
molecules that can interfere with STAT1 activity or expression are also discussed.
